GENinCode (LON:GENI) Stock Falls 10.8% – Should You Sell?

GENinCode Plc (LON:GENI)’s share price fell 10.8% during mid-day trading on Wednesday. The company traded as low as GBX 0.55 and last traded at GBX 0.58. Approximately 3,466,466 shares traded hands during trading, a decline of 27% from the average daily volume of 4,753,782 shares. The stock had previously closed at GBX 0.65.

GENinCode Trading Up 3.4%

The company’s 50 day moving average price is GBX 0.78 and its two-hundred day moving average price is GBX 0.98. The company has a debt-to-equity ratio of 4.75, a current ratio of 2.22 and a quick ratio of 15.88. The stock has a market capitalization of £4.52 million, a PE ratio of -0.47 and a beta of 0.59.

GENinCode (LON:GENI) last posted its quarterly earnings results on Tuesday, September 29th. The company reported GBX (0.38) earnings per share for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. As a group, analysts expect that GENinCode Plc will post -7.13 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.